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Abstract 
BACKGROUND: Psoriasis is a chronic inflammatory disease mediated by the immune system with increased 
proliferation of keratinocytes. The exact cause is unknown but as a multifactor, such as infection, trauma and 
psychological stress have been thought to play a role in its pathophysiology. Dopamine and serotonin are 
believed to have a strong role in stress conditions and also directly play a role in psoriasis.  
AIM: This study aimed to evaluate the role of dopamine, serotonin, and psychological stress in psoriasis. 
METHODS: This study used a case-control design involving 30 patients with psoriasis (as a case group) and 30 
healthy controls in the Dermatology and Venereology Polyclinic of Sanglah General Hospital Denpasar during the 
period December 2016 to February 2017. All samples were taken for venous blood examination serum dopamine 
and serotonin and analysed using the ELISA method. Statistical analysis using an independent t-test, partial 
correlation, receiver operator characteristic (ROC) curve, and logistic regression model. 
RESULT: There were significant differences in serotonin, dopamine, and stress index levels between groups with 
psoriasis and non-psoriasis (102.68 ± 25.44 Vs. 154.17 ± 20.90; p < 0.001), (437.13 ± 164.83 Vs. 138.11 ± 89.51; 
p < 0.001), and (138.5 ± 27.80 Vs. 92.55 ± 42.97; p < 0.001). Significant negative correlation was found between 
serotonin level and stress index (r = -0.366; p = 0.016) and between serotonin and dopamine (r = -0.634; p < 
0.001) but a positive correlation was found between dopamine and stress index (r = 0.459; p = 0.042). Serotonin 
and dopamine showed that it could be used as a biochemical predictive model for psoriasis (AUC > 0.7). 
Multivariable risk analysis model high serum dopamine was the most important risk factor for the occurrence of 
psoriasis (adjusted OR: 7.8; 95% CI: 3.45-15.57; p = 0.024) 
CONCLUSION: Serotonin and dopamine have a significant role in the pathophysiology of the occurrence of 
psoriasis, and psychological stress can affect psoriasis through its influence on serotonin and dopamine. 
 
 
 
 
Introduction 
 
Psoriasis is an autoimmune chronic-residual 
skin inflammatory disease, characterised by 
hyperproliferation of keratinocytes with erythema 
plaques, hyperkeratosis, and silvery-coated scales — 
symmetrical distribution of predilection areas of the 
extensor, scalp, lumbosacral region. The exact cause 
is unknown but several predisposing factors such as 
genetics, environmental factors, trauma, infection, 
drugs and psychological stress [1], [2]. The 
prevalence of psoriasis is 2% of the world population, 
but in America and Canada, it is 4.6% and 4.7%. 
Whereas in Asia around 0.4-0.7% [1], [3]. The number 
of new cases of psoriasis in our center tends to be 
rising from years to years. 
Currently, several studies prove psychological 
and neuroendocrine stress that can affect immune 
responses with clinical manifestations such as atopic 
dermatitis, alopecia, acne vulgaris, psoriasis, etc. 
Zangeneh and Fazeli found all stress hormones, 
catecholamines, corticotrophin releasing hormones 
(CRH), dopamine significantly increased in psoriasis. 
Interferon-gamma (IFN-γ) is a proinflammatory 
cytokine synthesised by T helper 1 cell (Th1), has 
been known to play a critical role in the pathogenesis 
of psoriasis. Psychological stressors lead to the 
dominant role of Th1 cells resulting in excessive IFN-γ 
synthesis [4], [5]. 
Dopamine is a neurotransmitter which 
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together with norepinephrine and epinephrine, is 
called catecholamine [6], [7]. Catecholamines function 
to regulate nerve function, neuroendocrine and 
immune systems. Dopamine can increase the activity 
of keratinocytes, which play a role in the release of 
cytokines and chemokines [7], [8]. Some studies show 
that cells in the immune system can be affected by 
dopamine. Dopamine agonists stimulate the 
production of interleukin (IL)-6 and IL-8, where IL-6 
and IL-8 play a role in the proliferation and 
differentiation of epidermal cells, besides IL-8 also 
stimulates chemotaxis of neutrophils and promotes 
acute inflammation. In keratinocyte cells of psoriasis 
patients found a high level of IL-8 expression and high 
dopamine serum receptors and can result in 
autoimmunity [8], [9]. 
Serotonin (5 hydroxytryptamines; 5-HT) is a 
neurotransmitter whose effect is mediated through 
different receptor interactions and consists of 14 
subtypes [10]. Serotonin is known as a 
neurotransmitter in the central nervous system and is 
involved in many processes including cognition and 
memory. In the other side, serotonin plays an 
essential role in vasoconstriction, heart rate in the 
cardiovascular and gastrointestinal systems [11]. 
Psychological stress can also reduce the synthesis of 
Serotonin and can affect many immunological 
processes and cause a decrease in proinflammatory 
cytokines such as tumour necrosis factor (TNF-α) [12], 
[13]. TNF-α plays an important role in the 
pathogenesis of psoriasis, selective activation of 
serotonin receptors with the 2,5-dimethoxy-4-
iodoamphetamine antagonist (DOI) produces a strong 
blockade of pro-inflammatory cytokines such as the 
Interleukin-6 cytokine (Il-6) and Interleukin-1b (IL-1b), 
then DOI antagonist also prevents TNF-α so and 
increase IL-6 level. If there is a decrease in serotonin, 
there will be an increase in proinflammatory cytokines 
that form the basis of the role mechanism of the 
inflammatory process in psoriasis [11], [12], [13].  
Based on this perspective, we would like to 
evaluate the role psychological stress causes a rise in 
dopamine and a decrease in serotonin reduction as a 
risk factor for psoriasis. 
 
 
Material and Method 
 
Study design and subject 
The study used a case-control design that 
took place in the Dermatology and Venereology 
Polyclinics in Sanglah General Hospital Denpasar, 
Bali-Indonesia during the period December 2016 to 
February 2017. The case group consisted of new or 
old case psoriasis who had not received any systemic 
treatment or two weeks had stopped treatment. 
Control is a healthy person or does not suffer from 
other allergic skin diseases. The two groups after 
being informed were asked to sign the informed 
consent sheet. Socio-demographic characteristics 
such as age, gender, body mass index were recorded 
and also the clinical type of psoriasis, clinical form of 
psoriasis and severity were calculated by the 
Psoriasis Area Severity Index (PASI) [14]. Stress 
index was evaluated using questions from the Social 
Readjustment Rating Scale by assessing a live event 
from an index of 10 – 200 [15]. Both groups performed 
venous blood collection to examine serum dopamine 
and serotonin using the method ELISA.  
 
Statistical analysis 
Statistical analysis was performed using 
SPSS version 25.0 for windows. Partial correlation 
was used to find a correlation between stress index, 
dopamine level and serotonin level by controlling age, 
gender, and body mass index. Independent sample t-
test or Mann Whitney U test was used to compare 
numerical variables such as serotonin serum, serum 
dopamine, and stress index in patients with psoriasis 
and non-psoriasis group. Receiver operator curve 
(ROC) analysis and risk analysis model using logistic 
regression were performed to determine the role of 
serotonin and dopamine in psoriasis. All tests were 
considered significant if the value of p < 0.05. 
 
 
Result 
 
Subject characteristics 
There were no significant differences in sex, 
age, body mass index between patients with psoriasis 
and non-psoriasis group (p > 0.05). However, the 
group of people with psoriasis tends to have a family 
history of psoriasis (59%). In the case group (psoriasis 
person) there were more people with a moderate 
psoriasis category (44%) based on the PASI category, 
with clinical types of maculopapular (64%), and type I 
psoriasis (70%) (Table 1). 
Table 1: Subject characteristics 
Characteristics 
Case (n = 60) 
Psoriasis 
Control (n = 60) 
Non-Psoriasis 
p-value 
Gender (n, %)    
Male 48 (49%) 50 (51%) 0.058 
Female 12 (54%) 10 (46%)  
Age (years) (Mean ± SD) 45.54 ± 11.2 46.21 ± 0.68 0.562 
Family history of psoriasis    
Yes 20 (72%) 4 (28%) 0.003* 
No 40 (44%) 26 (56%)  
BMI (n, %)    
High (> 25 kg/m
2
) 32 (59%) 22 (41%) 
0.063 
Normal (≤ 25 kg/m
2
) 28 (43%) 38 (57%) 
Type of Psoriasis (n, %)    
Type I 42 (70%) -  
Type II 18 (30%) -  
Psoriasis area severity index category (PASI) (n, %)    
Mild 20 (34%) -  
Moderate 26 (44%) -  
Severe 14 (22%) -  
Clinical type of psoriasis (n, %)    
Maculo-papular 38 (64%) -  
Gutate 16 (27%) -  
Erythrodermic psoriasis 6 (9%) -  
*Significant (p < 0.05). 
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Differences of stress index, serotonin 
level, and dopamine level between 
psoriasis and non-psoriasis group  
There were significant differences in serotonin 
levels between groups with psoriasis (102.68 ± 25.44) 
and non-psoriasis (154.17 ± 20.90) (p < 0.001), a 
person with psoriasis had lower serum serotonin 
levels compared to a non-psoriasis person. There 
were significant differences in dopamine levels 
between groups with psoriasis (437.13 ± 164.83) and 
non-psoriasis (138.11 ± 89.51) (p < 0.001), a person 
with psoriasis had higher serum dopamine levels 
compared to non-psoriasis. There were significant 
differences in stress index between groups with 
psoriasis (138.5 ± 27.80) and non-psoriasis (92.55 ± 
42.97) (p < 0.001), a person with psoriasis had a 
higher stress index compared to non-psoriasis (Table 
2). 
Table 2: Comparison of stress index, serotonin level, and 
dopamine level, between psoriasis and non-psoriasis group 
Variable 
Mean ± SD 
(Psoriasis) 
Mean ± SD 
(Non-Psoriasis) 
Mean 
differences 
95% CI p 
Dopamine 
serum 
(ng/ml) 
437.13 ± 164.83 138.11 ± 89.51 299.06 
230.50-
367.04 
< 0.001 
Serotonin 
serum 
(ng/ml) 
102.68 ± 25.44 154.17 ± 20.90 51.49 
39.14-
63.82 
< 0.001 
Stress index 138.5 ± 27.80 92.55 ± 42.97 45.95 
27.24-
64.65 
< 0.001 
 
Correlation between stress, serotonin, and 
dopamine 
A correlation test was carried out using partial 
correlation test by controlling the variables of age, 
sex, body mass index to determine the correlation 
between stress index, dopamine level, and serotonin 
level. There was a significant negative correlation 
between serotonin level and stress index (r = -0.366; p 
= 0.016), a significant negative correlation between 
serotonin and dopamine (r = -0.634; p < 0.001). This 
shows an inverse correlation between serotonin and 
dopamine and also between serotonin and stress 
index. However, there is a moderate positive 
correlation between dopamine and stress index (r = 
0.459; p = 0.042), this indicates that the higher stress 
index will be followed by an increase in serum 
dopamine (Table 3). 
Table 3: Correlation between stress index, dopamine level, and 
serotonin level after controlling for age, gender and body mass 
index 
Variable Stress Index 
n r (coefficient correlation) p 
Serotonin level 120 -0.366 0.016 
Dopamine level 0.458 0.042 
 Dopamine Level 
 n r (coefficient correlation) p 
Serotonin level 120 -0.634 < 0.001 
 
A predictive model of serotonin and 
dopamine as a biochemical marker in 
psoriasis 
Predictive models were carried out using 
analysis of receiver operator characteristics curve 
(ROC) on serotonin and dopamine parameters in 
psoriasis and non-psoriasis groups as the dependent 
variable in this study. Serotonin and dopamine 
showed that it could be used as a biochemical 
predictive model for psoriasis (AUC > 0.7) (Figure 1).  
 
Figure 1: ROC analysis of serotonin (left) and dopamine (right) as a 
biochemical marker in psoriasis 
 
Dopamine has sensitivity, specificity, and cut-
off values of 87%, 90%, and 320 ng/ml respectively 
and serotonin has a sensitivity value of 94%, 
specificity of 64%, and a cut-off value of 141 ng/ml 
(Table 4). 
Table 4: Area under the curve (AUC), cut-off value, sensitivity, 
and specificity of serotonin and dopamine in psoriasis 
Parameter AUC 95% CI Cutt-off 
value 
Sensitivity Specificity p 
Serotonin 0.912 0.82-0.94 141 ng/ml 94% 64% < 0.001 
Dopamine 0.937 0.87-0.98 320 ng/ml 87% 90% < 0.001 
 
Risk analysis model for serotonin and 
dopamine in psoriasis 
Risk analysis is based on the cut-off values of 
ROC of serum dopamine and serotonin, for serum 
dopamine values higher than 320 ng/ml classified as 
high dopamine serum levels, and lower ones are 
referred to as normal values. Then for serum 
serotonin, a value lower than cut off value is calcified 
as a low serum level, and a higher value is classified 
as normal. 
Table 5: Risk analysis model of serotonin and dopamine level 
in psoriasis 
Parameter 
 Univariable Model Multivariable Model 
 Psoriasis 
Non-
Psoriasis OR 95% CI p 
Adjus
ted 
OR 
95% CI P 
 n (%) n (%) 
Serotonin 
Low 42 (70%) 14 (24%) 
7.7 2.4-24.4 0.023* 5.4 2.23- 8.56 0.016* 
Normal 18 (30%) 46 (76%) 
Dopamine 
High 50 (83%) 16 (27%) 
15.6 4.7-30.8 0.019* 7.8 3.45- 15.57 0.024* 
Normal 10 (17%) 44 (73%) 
*Significant (p < 0.05). 
 
In univariable risk analysis mode low 
serotonin level (OR: 7.7; 95% CI: 2.4-24.4; p = 0.023) 
and high dopamine levels (OR: 15.6; 95% CI: 4.7-
30.8; p = 0.019) proved to be a risk factor of psoriasis. 
In a multivariable risk analysis model, high serum 
dopamine was the most important risk factor for the 
occurrence of psoriasis (adjusted OR: 7.8; 95% CI: 
3.45-15.57; p = 0.024). People with high-level serum 
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dopamine have a risk of 7.8 times higher to develop 
psoriasis compared to a person who has low serum 
dopamine level (Table 5). 
 
 
Discussion 
 
It has been widely known that stress has a 
close relationship with immunity in the human body 
[16]. In general, chronic stress can dampen the 
adaptive immune system and also innate immunity 
(natural killer cell activity), increasing the 
proinflammatory cytokine cascade. This occurs 
through activation of the hypothalamus-pituitary-
adrenal axis of the autonomic nervous system [12], 
[17]. It should be noted that the chronic increase in 
proinflammatory cytokines can act as a mechanism of 
feedback to the central nervous system (CNS) and 
have significant consequences on an individual's 
psychological well-being. In people with psoriasis, it is 
very common for a decrease in quality of life, 
depressed mood disorders, a tendency for a higher 
stress, social stigma, and problems in work caused by 
psoriasis itself. This condition makes psoriasis not 
something that is caused by immunology, but it is also 
characterised by an issue of mental disorders such as 
stress and depression [12], [16], [17]. 
Many studies have provided an increase in 
proinflammatory mediators in chronic stress disorders; 
these include increases in IL-1, IL-6, and TNF-α in the 
blood and cerebrospinal fluid [18], [19]. The 
proinflammatory cytokines in the central nervous 
system can affect the metabolism of monoamine 
neurotransmitters (dopamine, serotonin, and 
norepinephrine) which causes a decrease in 
availability, synthesis, and increased uptake of 
neurotransmitters that have a potential effect on 
inflammation and development of chronic stress into 
mood disorders [19]. Apart from that, proinflammatory 
cytokines such as TNF-α, IL-1, and IL-6 which are 
released by macrophages due to chronic inflammation 
and pro-inflammatory mediators produced by 
keratinocytes on the skin that experience psoriasis 
can reach the brain by penetrating the blood-brain 
barrier [12], [18]. Proinflammatory cytokines that have 
arrived in the brain will trigger a sickness behaviour 
(fatigue, fever, somnolence) which will then mediate 
the onset of depression and ongoing stress [10], [12]. 
Through this mechanism, it can be seen that stress 
affects inflammation and can trigger psoriasis as well 
as vice versa so that this will become a chain of 
never-ending circling pathophysiology [12], [20], [21]. 
It was also found in our study that stress correlated 
with dopamine levels which had a significant role in 
the occurrence of psoriasis. 
Serotonin (5-HT) is a neurotransmitter 
involved in many regulatory processes in the body 
and biological functions, psychological processes in 
the CNS, and also the role of peripheral tissue [21], 
[22]. In vivo studies, serotonin plays a role in cell 
signalling, and modulation of the peripheral immune 
system includes T cells, mast cell macrophages, 
dendritic cells, and platelets [23]. Specifically, the 
receptors of serotonin are expressed in T cells, where 
the result of sensitisation is the release of 
proinflammatory cytokines because of the response of 
serotonin secreted by mast cells which binds to the 
5HT-2 receptor [24]. The response also affects the 
maturation and proliferation of T cells. The ratio of 
Th1: Th2 is also affected by serotonin, a change in 
ratio <1 is associated with a higher risk of autoimmune 
disease. Serotonin receptors are also expressed in 
CD8 cells, monocytes, dendritic cells, mast cells [18], 
[25]. A decrease in serotonin will cause an increase in 
production of inflammatory mediators such as TNF-α, 
IFN-γ, IL-1β, IL-6, IL-8 which will carry out activation 
on nuclear factor-KB and induce activation of 
keratinocytes and trigger deterioration of keratinocytes 
and worsening of psoriasis symptom [13], [26], [27]. 
This is consistent with the findings of this study that 
low serotonin is a risk factor for psoriasis. 
It is well known that skin diseases such as 
psoriasis and atopic dermatitis are strongly influenced 
by the incidence of stress and dopamine has a very 
close relationship in the configuration of stress. 
Dopamine is an important neurotransmitter in the 
central nervous system and locomotive control, 
cognition, emotion, immunology, and neuroendocrine 
secretion [21]. Study by Mori et al. in the mouse 
animal model (in-vitro) shows that the intervention of 
dopamine 1 (D1) receptor antagonist (SCH 23390) 
decreases the expression of IL-4, IFN-γ observed in 
3-hour conditions (rapid phase immunological 
reactions) and 24 hours (slow phase immune 
reaction) on rat skin [28]. It can be seen that D1 like 
receptors are selectively expressed in Th2 cells, 
which suggests that dopamine can trigger the 
differentiation of Th2 cells. This indicates that D1-like 
dopamine receptor can induce degranulation of mast 
cells and trigger the release of proinflammatory 
cytokines. The role of dopamine in controlling Th2 
cells in modulating the immune system is very 
important in psoriasis [5], [28]. In this study found a 
significant association between high dopamine levels 
as a risk factor for psoriasis. 
The limitation in this study is that apart from 
psychological stress parameters, this study did not 
examine depression scale experienced in the study 
group, then the limited number of samples became a 
lack of generalisation to the population of the results 
of this study. 
In conclusion, serotonin and dopamine have a 
significant role in psoriasis, and psychological stress 
can affect serotonin and dopamine levels which have 
an indirect effect on psoriasis. More detailed research 
on the biomolecular mechanism of the role of 
serotonin and dopamine using a larger number of 
samples is needed. 
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